Morria Biopharma Reports Safety Results From Phase I Rhinitis Study
Posted on: Monday, 21 January 2008, 09:01 CST
Morria Biopharmaceuticals has reported encouraging preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis.
MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with an NAC. The protocol was double-blinded and placebo-controlled. The company said that, during the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.
Yuval Cohen, president of Morria, said: "We are entirely satisfied with these results. They mark an important milestone in our clinical development plan, which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar allergic rhinitis market."
Morria plans to initiate a Phase II efficacy clinical study with 175 patients, who will be treated for six days prior to allergen challenge.
Source: Datamonitor
Related Articles
- Morria Initiates Phase II Allergic Rhinitis Trial
- Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
- Morria Reports Safety Results of Phase I Allergy Drug
- Morria Announces Safety Results of Phase I Antiallergic Drug
- Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
- Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
- CDC Reorganizes Health and Safety Office
- Safety Leadership
- FAA Announces Decision on Child Safety Seats
 |
 |
User Comments (0)
RSS Feeds